Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

Cerenome highlighted SNO/ASCO clinical data supporting REYOBIQ CSF distribution and safety. It also pointed to CNSide’s ability to reduce monthly LM treatment costs by up to 47%. Overall, the update is supportive of differentiated efficacy/safety and potential cost-out, but appears incremental rather than market-wide.

Analysis

Cerenome highlighted SNO/ASCO clinical data supporting REYOBIQ CSF distribution and safety. It also pointed to CNSide’s ability to reduce monthly LM treatment costs by up to 47%. Overall, the update is supportive of differentiated efficacy/safety and potential cost-out, but appears incremental rather than market-wide.